Compugen (NASDAQ:CGEN) Upgraded at StockNews.com

StockNews.com upgraded shares of Compugen (NASDAQ:CGENFree Report) from a sell rating to a hold rating in a research report sent to investors on Friday.

Separately, Stifel Nicolaus lifted their target price on shares of Compugen from $3.00 to $4.00 and gave the stock a buy rating in a report on Tuesday, December 19th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of Moderate Buy and an average target price of $5.33.

Read Our Latest Research Report on Compugen

Compugen Stock Performance

Shares of CGEN stock opened at $2.33 on Friday. The company has a market capitalization of $201.82 million, a price-to-earnings ratio of -6.30 and a beta of 2.66. The company has a 50-day simple moving average of $1.75 and a 200 day simple moving average of $1.20. Compugen has a 52 week low of $0.53 and a 52 week high of $2.69.

Institutional Trading of Compugen

Several hedge funds and other institutional investors have recently bought and sold shares of the business. UBS Group AG raised its stake in Compugen by 12.7% in the 4th quarter. UBS Group AG now owns 314,697 shares of the biotechnology company’s stock worth $623,000 after purchasing an additional 35,443 shares in the last quarter. Janney Montgomery Scott LLC raised its stake in Compugen by 58.4% in the 4th quarter. Janney Montgomery Scott LLC now owns 21,700 shares of the biotechnology company’s stock worth $43,000 after purchasing an additional 8,000 shares in the last quarter. Silverarc Capital Management LLC raised its stake in Compugen by 6.1% in the 3rd quarter. Silverarc Capital Management LLC now owns 350,188 shares of the biotechnology company’s stock worth $326,000 after purchasing an additional 20,000 shares in the last quarter. Tocqueville Asset Management L.P. acquired a new stake in Compugen in the 3rd quarter worth about $71,000. Finally, Kingsview Wealth Management LLC acquired a new stake in Compugen in the 3rd quarter worth about $78,000. Institutional investors and hedge funds own 13.25% of the company’s stock.

About Compugen

(Get Free Report)

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.

Featured Articles

Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.